Related Experiment Video
Updated: Mar 21, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
AEG-1 as a predictor of sensitivity to neoadjuvant chemotherapy in advanced epithelial ovarian cancer
Yao Wang1, Xin Jin2, Hongtao Song3
1Department of Gynecology and Obstetrics, The General Hospital of Daqing Oil Field, Daqing, People's Republic of China.
Objectives:
Astrocyte elevated gene-1 (AEG-1) plays a critical role in tumor progression and chemoresistance. The aim of the present study was to investigate the protein expression of AEG-1 in patients with epithelial ovarian cancer (EOC) who underwent debulking surgery after neoadjuvant chemotherapy (NAC).
Materials And Methods:
The protein expression of AEG-1 was analyzed using immunohistochemistry in 162 patients with EOC. The relationship between AEG-1 expression and chemotherapy resistance was assessed using univariate and multivariate logistic regression analyses with covariate adjustments.
Results:
High AEG-1 expression was significantly associated with the International Federation of Gynecology and Obstetrics stage, age, serum cancer antigen-125 concentration, histological grade, the presence of residual tumor after the interval debulking surgery, and lymph node metastasis. Furthermore, AEG-1 expression was significantly higher in NAC-resistant disease than in NAC-sensitive disease (P<0.05). Multivariate analyses indicated that elevated AEG-1 expression predicted poor survival.
Conclusion:
Our findings indicate that AEG-1 may be a potential new biomarker for predicting chemoresistance and poor prognoses in patients with EOC.
